Aclaris Therapeutics, Pediatrix Therapeutics Ink License Deal For ATI-1777 In Greater China

Biopharmaceutical company Aclaris Therapeutics, Inc. (ACRS) and Chinese therapeutic company Pediatrix Therapeutics, Inc. announced that the companies have entered into a license agreement.

Under the license agreement, Aclaris has granted Pediatrix the exclusive rights to develop, manufacture and commercialize ATI-1777, Aclaris' investigational "soft" Janus kinase (JAK) 1/3 inhibitor, for any disease, including atopic dermatitis, in Greater China (Mainland China, Hong Kong, Macau and Taiwan).

Aclaris will retain the rights to develop, manufacture and commercialize ATI-1777 in the rest of the world.

Under the terms of the agreement, Aclaris will receive an upfront payment of $5 million. In addition, Aclaris is eligible to receive milestone payments of up to $91 million if certain development, regulatory and commercial objectives are achieved.

Aclaris is also eligible to receive a tiered royalty ranging from a low-to-high single digit percentage of net sales of ATI-1777 by Pediatrix in Greater China.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT